Transcriptomics Market – A Global and Regional Analysis: Focus on Product, Application, Technology, and End User – Analysis and Forecast, 2021-2031

$5,250$8,100

The healthcare experts have found the transcriptomics market to be one of the stable markets, and the global market is predicted to grow at a CAGR of 20.11% during the forecast period 2021-2031.

Clear

Description

Market Report Coverage – Transcriptomics Market

Market Segmentation

• Product (Instruments, Consumables, and Software)
• Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Microarray, In-Situ Hybridization (ISH), and Other Technologies)
• Application (Drug Discovery and Development, Diagnostics, Cell Biology, Single Cell Analysis, Gene Expression, and Other Applications)
• End User (Academic and Research Institutions, Biotechnology and Pharmaceutical Companies, and Other End Users (Hospitals, Clinics, and Diagnostics Labs)

Regional Segmentation

• North America: U.S., Canada
• Europe: Germany, U.K., France, Italy, Spain, and Rest-of-Europe
• Asia-Pacific: China, India, Japan, Australia, Singapore, and Rest-of-Asia-Pacific
• Latin America: Brazil, Mexico, Rest-of-Latin America
• Rest-of-the-World (RoW)

Market Growth Drivers

• Increasing Application of NGS and RNA-Sequencing in Transcriptomics Research
• Increase in Adoption of Personalized Medicine
• Continuous Advancement in the Products for Transcriptomics Research

Market Challenges

• High Cost and Maintenance of Next-Generation Sequencing and RNA-Sequencing Platform
• Lack of Tools for Computational Analysis
• Lack of Infrastructure and Expertise

Market Opportunities

• Expansion into New Research Application
• Expansion of Biomarker Discovery
• Use of Toxicogenomic to Promote Transcriptomics Research

Key Companies Profiled

10x Genomics, Agilent Technologies, Inc., ANGLE plc, Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Bio-Techne, BioSypder, Inc., Cytiva, Fluidigm Corporation, Illumina, Inc., Menarini Silicon Biosystems, NanoString, Pacific Biosciences of California, Inc., PerkinElmer Inc., QIAGEN, Takara Bio Inc., Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

• How is next-generation sequencing technology affecting the transcriptomics market?
• What are the major market drivers, challenges, and opportunities in the global transcriptomics market?
• What are the underlying structures resulting in the emerging trends within the global transcriptomics market?
• How is the COVID-19 pandemic impacting the global transcriptomics market landscape?
• What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to transcriptomics?
• What are the potential entry barriers expected to be faced by the companies willing to enter a particular region for the development of transcriptomics?
• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment?
• What are the growth opportunities for the companies in the region of their operation?
• What are the major applications for the companies in the region of their operation?
• Who are the leading players with significant offerings in the global transcriptomics market?
• Which companies are anticipated to be highly disruptive in the future, and why?
• What are the current unmet needs that are being faced in the global transcriptomics market?

Market Overview

The growth of the transcriptomics market is expected to be driven by the decrease in the cost of sequencing, the global increase in the application of next-generation sequencing and RNA sequencing in transcriptomics, and the advancement of the products. However, there are significant challenges restraining the market growth, such as the high cost and maintenance of next-generation sequencing and RNA sequencing platforms and the lack of tools for computational analysis. The transcriptomics approach has been able to decipher the mechanism of complex bulk tissue, giving a deep understanding of heterogeneous cell populations. With the co-analysis of molecules, such as RNA, and protein, at a single cell level, the researchers are able to unearth the regulation mechanism associated with RNA transcription and protein translation.

The healthcare experts have found the transcriptomics market to be one of the stable markets, and the global market is predicted to grow at a CAGR of 20.11% during the forecast period 2021-2031.

The transcriptomics market is an emerging market with huge growth potential. Recent technological advancements are facilitating the adoption of the technology at a rapid pace. Transcriptomics offers the ability to isolate a single cell with specific phenotypes from a heterogeneous mixture, along with gene expression analysis and protein expression analysis. The unique feature of transcriptomics technology to integrate the data from various molecules and from different cells to study cell-to-cell differentiation enables the study of mechanisms that are visible at a transcriptomic level.

Competitive Landscape

The growth in this market is expected to be driven by the decrease in the cost of sequencing, the global increase in the application of next-generation sequencing and RNA sequencing in transcriptomics, and the advancement of products launches. The growth of other technologies, such as in-situ hybridization, can be attributed to the increased clinical research to understand the involvement of molecular pathology in the diagnosis and prognosis of genetic disorders. Based on region, North America holds the largest share in the market, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. However, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Base Year

2021

Base Market Size

$5.39 Billion in 2021

Currency/Unit

USD

Forecast Year

2031

Market Size Forecast

$33.68 Billion by 2031

CAGR

20.11%

Table of Contents

1 Markets
1.1 Industry Outlook
1.1.1 Global Transcriptomics Market Overview
1.1.2 Transcriptomics Cell Sequencing Data and Bioinformatics Analysis
1.1.2.1 Analysis of Genomic Data
1.1.2.2 Analysis of Transcriptome Sequencing
1.2 Product Definition
1.2.1 Inclusion and Exclusion
1.3 Global Transcriptomics Devices Market Size and Forecast
1.4 Global Transcriptomics Market Size and Forecast – Realistic, Optimistic, and Conservative Growth Scenario
1.4.1 Realistic Growth Scenario
1.4.2 Conservative Growth Scenario
1.4.3 Optimistic Growth Scenario
1.5 Current Global Transcriptomics Market Landscape
1.5.1 Multi-Omics
1.5.2 Computational Analysis in Genomics and Transcriptomics
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.2.1 Increasing Application of NGS and RNA-Sequencing in Transcriptomics Research
1.6.2.2 Increase in Adoption of Personalized Medicine
1.6.2.3 Continuous Advancement in the Products for Transcriptomics Research
1.6.3 Market Restraints
1.6.3.1 High Cost and Maintenance of Next-Generation Sequencing and RNA-Sequencing Platform
1.6.3.2 Lack of Tools for Computational Analysis
1.6.3.3 Lack of Infrastructure and Expertise
1.6.4 Market Opportunities
1.6.4.1 Expansion into New Research Application
1.6.4.2 Expansion of Biomarker Discovery
1.6.4.3 Use of Toxicogenomic to Promote Transcriptomics Research
1.7 COVID-19 Impact on Global Transcriptomics Market
1.7.1 Impact on Market Size
1.7.2 Impact on Transcriptomics Practices
1.8 Competitive Landscape
1.8.1 Acquisitions
1.8.2 Synergistic Activities
1.8.3 Product Launches and Upgradations
1.8.4 Business Expansion
1.8.5 Market Share Analysis
1.8.6 Growth Share Analysis
1.9 Industry Insights
1.9.1 Legal Requirements and Framework in the U.S.
1.9.2 FDA Regulations
1.9.3 Legal Requirements and Framework in Europe
1.9.3.1 U.K.
1.9.3.2 Germany
1.9.4 Legal Requirements and Framework in Asia-Pacific
1.9.4.1 China
1.9.4.2 Japan
1.9.4.2.1 Pharmaceuticals and Medical Devices Agency (PMDA)
1.9.4.2.2 Ministry of Health, Labour, and Welfare (MHLW)
1.9.4.3 India
1.10 Patent Analysis
1.10.1 Patent Filing Trend
2 Products
2.1 Overview
2.1.1 Instruments
2.1.2 Consumables
2.1.3 Software
3 Technology
3.1 Overview
3.1.1 Next-Generation Sequencing
3.1.2 Polymerase Chain Reaction (PCR)
3.1.3 Microarray
3.1.4 In-Situ Hybridization (ISH)
3.1.5 Other Technologies
4 Application
4.1 Overview
4.1.1 Drug Discovery and Development
4.1.2 Diagnostics
4.1.3 Cell Biology
4.1.4 Single Cell Analysis
4.1.5 Gene Expression
4.1.6 Other Applications
5 End-User
5.1 Overview
5.1.1 Academic and Research Institutions
5.1.2 Biotechnology and Biopharmaceutical Companies
5.1.3 Other End Users (Hospitals, Clinics, and Diagnostic Labs)
6 Regions
6.1 Overview
6.2 North America
6.2.1 North America Transcriptomics Market (by Application)
6.2.2 U.S.
6.2.3 Canada
6.3 Europe
6.3.1 Europe Transcriptomics Market (by Application)
6.3.2 Germany
6.3.3 U.K.
6.3.4 France
6.3.5 Italy
6.3.6 Spain
6.3.7 Rest-of-Europe
6.4 Asia-Pacific
6.4.1 Asia-Pacific Transcriptomics Market (by Application)
6.4.2 China
6.4.3 India
6.4.4 Japan
6.4.5 Australia
6.4.6 Singapore
6.4.7 Rest-of-Asia-Pacific
6.5 Latin America (LATAM)
6.5.1 Latin America Transcriptomics Market (by Application)
6.5.2 Brazil
6.5.3 Mexico
6.5.4 Rest-of-Latin America
6.6 Rest-of-the-World (RoW)
6.6.1 Rest-of-the-World Transcriptomics Market (by Application)
7 Markets – Competitive Benchmarking & Company Profiles
7.1 Competitive Benchmarking
7.2 10x Genomics
7.2.1 Company Overview
7.2.2 Role of 10x Genomics in the Global Transcriptomics Market
7.2.3 Financials
7.2.4 Key Insights About Financial Health of the Company
7.2.5 SWOT Analysis
7.3 Agilent Technologies, Inc.
7.3.1 Company Overview
7.3.2 Role of Agilent Technologies, Inc. in the Global Transcriptomics Market
7.3.3 Financials
7.3.4 Key Insights About Financial of the Company
7.3.5 SWOT Analysis
7.4 ANGLE plc
7.4.1 Company Overview
7.4.2 Role of ANGLE plc in the Global Transcriptomics Market
7.4.3 SWOT Analysis
7.5 Becton, Dickinson and Company (BD)
7.5.1 Company Overview
7.5.2 Role of Becton, Dickinson and Company (BD) in the Global Transcriptomics Market
7.5.3 Financials
7.5.4 Key Insights About Financial Health of the Company
7.5.5 SWOT Analysis
7.6 Bio-Rad Laboratories, Inc.
7.6.1 Company Overview
7.6.2 Role of Bio-Rad Laboratories, Inc. in the Global Transcriptomics Market
7.6.3 Financials
7.6.4 Key Insights About Financial Health of the Company
7.6.5 SWOT Analysis
7.7 Bio-Techne
7.7.1 Company Overview
7.7.2 Role of Bio-Techne in the Global Transcriptomics Market
7.7.3 Financials
7.7.4 Key Insights About Financial Health of the Company
7.7.5 SWOT Analysis
7.8 BioSypder, Inc.
7.8.1 Company Overview
7.8.2 Role of BioSypder, Inc. in the Global Transcriptomics Market
7.8.3 SWOT Analysis
7.9 Cytiva
7.9.1 Company Overview
7.9.2 Role of Cytiva in the Global Transcriptomics Market
7.9.3 SWOT Analysis
7.10 Fluidigm Corporation
7.10.1 Company Overview
7.10.2 Role of Fluidigm Corporation in the Global Transcriptomics Market
7.10.3 Financials
7.10.4 Key Insights About Financial Health of the Company
7.10.5 SWOT Analysis
7.11 Illumina, Inc.
7.11.1 Company Overview
7.11.2 Role of Illumina, Inc. in the Global Transcriptomics Market
7.11.3 Financials
7.11.4 Key Insights About Financial Health of the Company
7.11.5 SWOT Analysis
7.12 Menarini Silicon Biosystems
7.12.1 Company Overview
7.12.2 Role of Menarini Silicon Biosystems in the Global Transcriptomics Market
7.12.3 SWOT Analysis
7.13 NanoString
7.13.1 Company Overview
7.13.2 Role of NanoString in the Global Transcriptomics Market
7.13.3 Financials
7.13.4 Key Insights About Financial Health of the Company
7.13.5 SWOT Analysis
7.14 Pacific Biosciences of California, Inc.
7.14.1 Company Overview
7.14.2 Role of Pacific Biosciences of California, Inc. in the Global Transcriptomics Market
7.14.3 Financials
7.14.4 Key Insights About Financial Health of the Company
7.14.5 SWOT Analysis
7.15 PerkinElmer Inc.
7.15.1 Company Overview
7.15.2 Role of PerkinElmer Inc. in the Global Transcriptomics Market
7.15.3 Financials
7.15.4 Key Insights About Financial Health of the Company
7.15.5 SWOT Analysis
7.16 QIAGEN
7.16.1 Company Overview
7.16.2 Role of QIAGEN in the Global Transcriptomics Market
7.16.3 Financials
7.16.4 Key Insights About Financial Health of the Company
7.16.5 SWOT Analysis
7.17 Takara Bio Inc.
7.17.1 Company Overview
7.17.2 Role of Takara Bio Inc. in the Global Transcriptomics Market
7.17.3 Financials
7.17.4 Key Insights About Financial Health of the Company
7.17.5 SWOT Analysis
7.18 Thermo Fisher Scientific Inc.
7.18.1 Company Overview
7.18.2 Role of Thermo Fisher Scientific Inc. in the Global Transcriptomics Market
7.18.3 Financials
7.18.4 Key Insights About Financial Health of the Company
7.18.5 SWOT Analysis
List of Tables
Table 1: RNA-Sequencing Methodologies
Table 2: RNA-Sequencing De Novo Assembly Software
Table 3: Sequencing Technology Platforms for RNA-Sequencing
Table 4: Cost of NGS Per Sample on Different Applications
Table 5: Biomarkers for Various Diseases
Table 6: COVID-19 Impact on Global Transcriptomics Market
Table 7: Products Launched by Various Manufacturers for Transcriptomic Research
Table 8: Instruments Offered by Key Players
Table 9: Consumables Offered by Key Players
Table 10: Software Offered by Key Players
Table 11: NGS-Based Products for Transcriptomics
Table 12: PCR-Based Products for Transcriptomics
Table 13: Microarray-Based Products for Transcriptomics
Table 14: In-Situ Hybridization (ISH)-Based Products for Transcriptomics
List of Figures
Figure 1: Global Transcriptomics Market (Realistic and Optimistic Scenario), $Billion, 2020-2031
Figure 2: Global Transcriptomics Market, Market Dynamics
Figure 3: Share of Key Market Strategies and Developments, January2017-August 2021
Figure 4: Global Transcriptomics Market Snapshot, $Billion, 2020-2031
Figure 5: Global Transcriptomics Market (by Product), $Billion, 2020 vs. 2031
Figure 6: Global Transcriptomics Market (by Technology), $Billion, 2020 vs. 2031
Figure 7: Global Transcriptomics Market (by Application), $Billion, 2020 vs. 2031
Figure 8: Global Transcriptomics Market (by End User), $Billion, 2020 vs. 2031
Figure 9: Global Transcriptomics Market (by Region), $Billion, 2020 vs. 2031
Figure 10: Global Transcriptomics Market Research Methodology
Figure 11: Global Transcriptomics Market: Segmentation
Figure 12: Multi-Omics Approach for Central Dogma
Figure 13: Global Transcriptomics Market Incremental Opportunity, $Billion, 2020-2031
Figure 14: Global Transcriptomics Market Size and Growth Potential (Realistic Scenario), $Billion, 2020-2031
Figure 15: Global Transcriptomics Market Size and Growth Potential (Conservative Scenario), $Billion, 2020-2031
Figure 16: Global Transcriptomics Market Size and Growth Potential (Optimistic Scenario), $Billion, 2020-2031
Figure 17: Global Transcriptomics Market – Market Dynamics
Figure 18: Personalized Care for Cancer Patients
Figure 19: Impact of COVID-19 on Transcriptomics Market
Figure 20: Share of Key Developments and Strategies, January 2017–August 2021
Figure 21: Share of Acquisitions (by Company), January 2017-August 2021
Figure 22: Synergistic Activities Share (by Company), January 2017-August 2021
Figure 23: Product Launches and Upgradations (by Company), January 2017–August 2021
Figure 24: Share of Business Expansion (by Company), January 2017-August 2021
Figure 25: Market Share Analysis for Global Transcriptomics Market, $Billion, 2019 and 2020
Figure 26: Growth Share Analysis of Global Transcriptomics Market (by Technology), 2020-2031
Figure 27: Responsibilities of the National Medical Products Administration (NMPA)
Figure 28: Approved Next-Generation Sequencing (NGS) Panels in Japan
Figure 29: Year-Wise Analysis of Patents Related to Transcriptomics, January 2017-August 2021
Figure 30: Country-Wise Analysis (January 2017- August 2021) of Patents Related to Transcriptomics
Figure 31: Share of Global Transcriptomics Market (by Product), $Billion, 2020 and 2031
Figure 32: Global Transcriptomics Market (Instruments), $Billion, 2020-2031
Figure 33: Global Transcriptomics Market (Consumables), $Billion, 2020-2031
Figure 34: Global Transcriptomics Market (Software), $Billion, 2020-2031
Figure 35: Share of Global Transcriptomics Market (by Technology), $Billion, 2020 and 2031
Figure 36: Global Transcriptomics Market (Next-Generation Sequencing), $Billion, 2020-2031
Figure 37: Global Transcriptomics Market (Polymerase Chain Reaction), $Billion, 2020-2031
Figure 38: Global Transcriptomics Market (Microarray), $Billion, 2020-2031
Figure 39: Global Transcriptomics Market (In-Situ Hybridization), $Billion, 2020-2031
Figure 40: Global Transcriptomics Market (Other Technologies), $Billion, 2020-2031
Figure 41: Global Transcriptomics Market (by Application), $Billion, 2020 and 2031
Figure 42: Global Transcriptomics Market (Drug Discovery and Development), $Billion, 2020-2031
Figure 43: Global Transcriptomics Market (Diagnostics), $Billion, 2020-2031
Figure 44: Global Transcriptomics Market (Cell Biology), $Billion, 2020-2031
Figure 45: Global Transcriptomics Market (Single Cell Analysis), $Billion, 2020-2031
Figure 46: Global Transcriptomics Market (Gene Expression), $Billion, 2020-2031
Figure 47: Global Transcriptomics Market (Other Applications), $Billion, 2020-2031
Figure 48: Global Transcriptomics Market (by End User), $Billion, 2020 and 2031
Figure 49: Global Transcriptomics Market (Academic and Research Institutions), $Billion, 2020-2031
Figure 50: Global Transcriptomics Market (Biotechnology and Biopharmaceutical Companies), $Billion, 2020-2031
Figure 51: Global Transcriptomics Market (Other End Users), $Billion, 2020-2031
Figure 52: Global Transcriptomics Market (by Region), $Billion, 2020-2031
Figure 53: Share of North America Transcriptomics Market Revenue (by Country), $Billion, 2020 and 2031
Figure 54: North America: Market Dynamics
Figure 55: North America Transcriptomics Market (by Application), $Billion, 2020 and 2031
Figure 56: U.S. Transcriptomics Market, $Billion, 2020-2031
Figure 57: Canada Transcriptomics Market, $Billion, 2020-2031
Figure 58: Europe Transcriptomics Market (by Country), $Billion, 2020 and 2031
Figure 59: Europe: Market Dynamics
Figure 60: Europe Transcriptomics Market (by Application), $Billion, 2020 and 2031
Figure 61: Germany Transcriptomics Market, $Billion, 2020-2031
Figure 62: U.K. Transcriptomics Market, Billion, 2020-2031
Figure 63: France Transcriptomics Market, $Billion, 2020-2031
Figure 64: Italy Transcriptomics Market, $Billion, 2020-2031
Figure 65: Spain Transcriptomics Market, Billion, 2020-2031
Figure 66: Rest-of-Europe Transcriptomics Market, Billion, 2020-2031
Figure 67: APAC: Market Dynamics
Figure 68: Asia-Pacific Transcriptomics Market (by Country), $Billion, 2020 and 2031
Figure 69: Asia-Pacific Transcriptomics Market (by Application), $Billion, 2020 and 2031
Figure 70: China Transcriptomics Market, $Billion, 2020-2031
Figure 71: India Transcriptomics Market, $Billion, 2020-2031
Figure 72: Japan Transcriptomics Market, $Billion, 2020-2031
Figure 73: Australia Transcriptomics Market, Billion, 2020-2031
Figure 74: Singapore Transcriptomics Market, Billion, 2020-2031
Figure 75: Rest-of-Asia-Pacific Transcriptomics Market, $Billion, 2020-2031
Figure 76: LATAM: Market Dynamics
Figure 77: Latin America Transcriptomics Market (by Country), $Billion 2020-2031,
Figure 78: Latin America Transcriptomics Market (by Application), $Billion, 2020 and 2031
Figure 79: Brazil Transcriptomics Market, $Billion, 2020-2031
Figure 80: Mexico Transcriptomics Market, Billion, 2020-2031
Figure 81: Rest-of-Latin America Transcriptomics Market, $Billion, 2020-2031
Figure 82: Rest-of-the-World Transcriptomics Market, $Billion, 2020-2031
Figure 83: Rest-of-the-World Transcriptomics Market (by Application), $Billion, 2020 and 2031
Figure 84: Share of Key Company Profiles
Figure 85: 10x Genomics: Product Portfolio
Figure 86: 10x Genomics: Overall Financials, 2018-2020
Figure 87: 10x Genomics: Revenue (by Segment), 2018-2020
Figure 88: 10x Genomics: Revenue (by Region), 2018-2020
Figure 89: 10x Genomics: R&D Expenditure, 2018-2020
Figure 90: 10x Genomics: SWOT Analysis
Figure 91: Agilent Technologies, Inc.: Product Portfolio
Figure 92: Agilent Technologies, Inc.: Overall Financials, 2018-2020
Figure 93: Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020
Figure 94: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
Figure 95: Agilent Technologies, Inc.: R&D Expenditure, 2018-2020
Figure 96: Agilent Technologies, Inc.: SWOT Analysis
Figure 97: ANGLE plc.: Product Portfolio
Figure 98: ANGLE plc: SWOT Analysis
Figure 99: Becton, Dickinson and Company (BD): Product Portfolio
Figure 100: Becton, Dickinson and Company (BD): Overall Financials, 2018-2020
Figure 101: Becton, Dickinson and Company (BD): Revenue (by Segment), 2018-2020
Figure 102: Becton, Dickinson and Company (BD): Revenue (by Region), 2018-2020
Figure 103: Becton, Dickinson and Company (BD): R&D Expenditure, 2018-2020
Figure 104: Becton, Dickinson and Company (BD): SWOT Analysis
Figure 105: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 106: Bio-Rad Laboratories, Inc.: Overall Financials, 2018-2020
Figure 107: Bio-Rad Laboratories, Inc.: Revenue (by Business Segment), 2018-2020
Figure 108: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2018-2020
Figure 109: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2018-2020
Figure 110: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 111: Bio-Techne: Product Portfolio
Figure 112: Bio-Techne: Overall Financials, 2018-2020
Figure 113: Bio-Techne.: Revenue (by Segment), 2018-2020
Figure 114: Bio-Techne.: Revenue (by Region), 2018-2020
Figure 115: Bio-Techne: R&D Expenditure, 2018-2020
Figure 116: Bio-Techne: SWOT Analysis
Figure 117: BioSypder, Inc.: Product Portfolio
Figure 118: BioSypder, Inc.: SWOT Analysis
Figure 119: Cytiva: Product Portfolio
Figure 120: Cytiva: SWOT Analysis
Figure 121: Fluidigm Corporation: Product Portfolio
Figure 122: Fluidigm Corporation: Overall Financials, 2018-2020
Figure 123: Fluidigm Corporation: Revenue (by Segment), 2018-2020
Figure 124: Fluidigm Corporation: Revenue (by Region), 2018-2020
Figure 125: Fluidigm Corporation: R&D Expenditure, 2018-2020
Figure 126: Fluidigm Corporation: SWOT Analysis
Figure 127: Illumina, Inc.: Product Portfolio
Figure 128: Illumina, Inc.: Overall Financials, 2018-2020
Figure 129: Illumina, Inc.: Revenue (by Segment), 2018-2020
Figure 130: Illumina, Inc.: Revenue (by Region), 2018-2020
Figure 131: Illumina, Inc.: R&D Expenditure, 2018-2020
Figure 132: Illumina, Inc.: SWOT Analysis
Figure 133: Menarini Silicon Biosystems.: Product Portfolio
Figure 134: Menarini Silicon Biosystems.: SWOT Analysis
Figure 135: NanoString: Product Portfolio
Figure 136: NanoString: Overall Financials, 2018-2020
Figure 137: NanoString: Revenue (by Segment), 2018-2020
Figure 138: NanoString: Revenue (by Region), 2018-2020
Figure 139: NanoString: R&D Expenditure, 2018-2020
Figure 140: NanoString: SWOT Analysis
Figure 141: Pacific Biosciences of California, Inc.: Product Portfolio
Figure 142: Pacific Biosciences of California, Inc.: Overall Financials, 2018-2020
Figure 143: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2018-2020
Figure 144: Pacific Biosciences of California, Inc.: Revenue (by Region), 2018-2020
Figure 145: Pacific Biosciences of California, Inc.: R&D Expenditure, 2018-2020
Figure 146: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 147: PerkinElmer Inc.: Product Portfolio
Figure 148: PerkinElmer Inc.: Overall Financials, 2018-2020
Figure 149: PerkinElmer Inc.: Revenue (by Segment), 2018-2020
Figure 150: PerkinElmer Inc: Revenue (by Region), 2018-2020
Figure 151: PerkinElmer Inc. R&D Expenditure, 2018-2020
Figure 152: PerkinElmer Inc.: SWOT Analysis
Figure 153: QIAGEN: Portfolio
Figure 154: QIAGEN: Overall Financials, 2018-2020
Figure 155: QIAGEN: Revenue (by Segment), 2018-2020
Figure 156: QIAGEN: Revenue (by Region), 2018-2020
Figure 157: QIAGEN: R&D Expenditure, 2018-2020
Figure 158: QIAGEN: SWOT Analysis
Figure 159: Takara Bio Inc.: Product Portfolio
Figure 160: Takara Bio Inc.: Overall Financials, 2018-2020
Figure 161: Takara Bio Inc.: Revenue (by Business Segment), 2018-2020
Figure 162: Takara Bio Inc.: R&D Expenditure, 2018-2020
Figure 163: Takara Bio Inc.: SWOT Analysis
Figure 164: Thermo Fisher Scientific, Inc.: Product Portfolio
Figure 165: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020
Figure 166: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2018-2020
Figure 167: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
Figure 168: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 169: Thermo Fisher Scientific Inc.: SWOT Analysis